Skip to content

MDMA and psychedelic-assisted therapy: all studies

Page 3 of 15: studies 21 to 30 of 143, newest first. Back to the MDMA and psychedelic-assisted therapy overview

Research

MDMA-Assisted Treatment for PTSD, Anxiety, and Depression: A Visualized Literature Analysis over 30 Years.

Current Medicinal Chemistry June 2, 2025 Jinlong Zhang, Xingxing Dang, Jiang Lin et al.

The incidence of psychiatric disorders, such as post-traumatic stress disorder (PTSD), anxiety, and depression, has been steadily increasing, while current treatment approaches remain limited in efficacy. As a result, there is an urgent need to explore more effective therapeutic interventions. In recent years, MDMA (3,4- methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) has emerged as a...

MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up.

Alcohol and alcoholism (Oxford, Oxfordshire) May 14, 2025 Hannah Thurgur, Ben Sessa, Laurie Higbed et al. 3 citations

Safety and tolerability data from the first open-label feasibility study of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for alcohol use disorder was recently published. This paper presents a Bayesian analysis of the impact of MDMA-assisted psychotherapy on treatment success, defined as 2-level reduction in the World Health Organization (WHO) drinking risk at the 3 months...

Exploring the potential of psychedelic-assisted psychotherapy for moral injury: A scoping review.

Progress in neuro-psychopharmacology & biological psychiatry April 2, 2025 Viktoriia Kurkova, Olga Winkler, Andrew J. Greenshaw et al.

This scoping review addresses the need to comprehensively explore the potential of psychedelic-assisted psychotherapy (PAP) to facilitate recovery from moral injury. Moral injury (MI), characterized by profound psychological distress arising from morally challenging experiences, has garnered increased attention as a complex mental health concern with significant functional sequelae, especially...

MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward.

CNS Drugs April 1, 2025 Balwinder Singh 6 citations

Trauma is prevalent, with lifetime estimates of traumatic exposure ranging from 70% for a single event to 31% for multiple events. While many recover, a subset develop post-traumatic stress disorder (PTSD), a debilitating condition characterized by distressing memories, avoidance behaviors, hyperarousal, and mood disturbances. The National Comorbidity Survey reports a lifetime PTSD prevalence...

Safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in post-traumatic stress disorder: An overview of systematic reviews and meta-analyses.

The Australian and New Zealand journal of psychiatry April 1, 2025 Alene Sze Jing Yong, Suzie Bratuskins, Musa Samir Sultani et al. 16 citations

To critically evaluate published and unpublished systematic reviews and meta-analyses on the safety and efficacy of methylenedioxymethamphetamine-assisted psychotherapy for post-traumatic stress disorder. Six bibliometric databases and grey literature were searched from inception to 9 May 2024 for systematic reviews on the safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted...

A systematic review of participant diversity in psychedelic-assisted psychotherapy trials.

Psychiatry Research March 1, 2025 Stephanie L. Haft, Amanda E. Downey, Marissa Raymond-Flesch et al. 22 citations

A lack of diverse and representative participant samples in mental health intervention research perpetuates mental health disparities. This issue has become a salient concern in studies of psychedelic-assisted psychotherapy (PAT), which is emerging as a promising mental health intervention. This systematic review evaluates the reporting, representation, and analysis of participant...

DOI: 10.1016/j.psychres.2025.116359 (opens in new tab) Full text (opens in new tab) Psychedelic research MDMA Therapy Systematic review Clinical diversity +2

Transdiagnostic use of 3,4-methylenedioxymethamphetamine-assisted therapy to treat obsessive-compulsive disorder.

The British journal of psychiatry : the journal of mental science February 26, 2025 Ziad Saade, Alex S Keuroghlian 2 citations

This article explores the potential of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy to enhance exposure and response prevention in obsessive-compulsive disorder treatment. We discuss the mechanisms of MDMA, including fear extinction, psychological flexibility, and empathogenic effects that may improve adherence and efficacy, as well as highlighting important safety considerations...

DOI: 10.1192/bjp.2024.277 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Obsessive–compulsive disorders Psychological treatments Psychotherapy +3

The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD.

Contemporary clinical trials communications February 1, 2025 Jessica L Maples-Keller, Boadie W Dunlop, Barbara O Rothbaum 5 citations

This article describes the rationale and the specific methods for an open label pilot trial of 100 mg MDMA in combination with massed exposure therapy for PTSD, a treatment which involves daily exposure therapy sessions for two weeks which has found to be effective. We review the need for novel PTSD treatments and the existing research on MDMA-assisted therapy, and then describe the rationale...

Therapeutic Potential of MDMA- and Psychedelic-Assisted Psychotherapy for Adolescent Depression and Trauma.

Current Psychiatry Reports February 1, 2025 Jamarie Geller, Eric Whitney 3 citations

There is a mental health crisis affecting youth, and the utility of existing treatments is often limited by lack of effectiveness and tolerability. The aim of this review is to report on outcomes of clinical trials for psilocybin-assisted psychotherapy for adults with depression and MDMA-assisted psychotherapy for adults with post-traumatic stress disorder (PTSD) and discuss recommendations for...

MDMA-assisted therapy: challenges, clinical trials, and the future of MDMA in treating behavioral disorders.

CNS Spectrums January 30, 2025 Steve O'Brien, David Nutt 5 citations

This chapter explores the complex and controversial path of MDMA-assisted therapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) and other behavioral disorders. It covers MDMA's history from research to recreation to medicine, the pivotal trials, and the challenges faced by researchers. Despite recent setbacks for the clinical application of MDMA, the chapter argues that it holds...